HealthCare Global Enterprises Limited
HCG.BO
Bombay Stock Exchange651.25
INR
-7.00
- -
HealthCare Global Enterprises Limited
HCG.BO
(Bombay Stock Exchange)
Recent
price
651.25
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- HealthCare Global Enterprises Limited specializes in providing comprehensive specialty healthcare focused primarily on oncology and fertility treatments. The company operates the largest cancer care network in India under the HCG brand, offering services including cancer diagnosis, radiation therapy, medical oncology, surgical oncology, immunotherapy, and palliative care across more than 25 cancer centers nationwide. It also provides fertility treatment services under the Milann brand, including in-vitro fertilization, gynecological endoscopy, and fertility preservation at multiple facilities. Additionally, HCG manages multispecialty hospitals delivering tertiary care in internal medicine, gastroenterology, urology, cardiology, and critical care, with advanced diagnostic and screening services such as PET-CT scans. The company’s operations span key Indian regions including Karnataka, Gujarat, Maharashtra, East India, and North India, and it has expanded internationally with a step-down subsidiary in Kenya. Founded in 1989 and headquartered in Bangalore, India, HealthCare Global Enterprises has continuously invested in cutting-edge technology, including linear accelerators, robotic surgery, and digital oncology platforms to enhance treatment outcomes. Recent major developments include the acquisition of a 10% equity stake in Cancer Care Kenya Limited in 2025, strengthening its international presence. There have been strategic senior management appointments such as the CEO Manish Mattoo assuming office in mid-2025 and new leadership in domestic sales and marketing roles. In 2025, prominent institutional investors, including Morgan Stanley and Nippon India Mutual Fund, acquired a significant equity stake from private equity firm CVC Capital Partners. The firm also continues to expand its network by increasing its cancer care centers and enhancing its fertility and diagnostic services, focusing on operational efficiency and technology-driven patient care delivery. HealthCare Global Enterprises generates revenue predominantly from oncology and fertility care services, supported by its extensive hospital network with around 1,700 operational beds and over 400 oncology specialists. Its business segments encompass cancer diagnosis and treatment, multi-specialty tertiary care, fertility services, and advanced screening diagnostics, servicing a diverse patient base across India and selected international markets. The company pursues research and development initiatives, engaging in clinical trials and collaborations with academic institutions to advance oncology treatments. The firm remains committed to expanding accessible high-quality healthcare, particularly in underserved Tier II and Tier III cities in India, leveraging technology and a patient-centric approach to deliver value-based medicine. This comprehensive specialty healthcare provider holds a commanding position as one of India’s largest private cancer care networks and fertility services providers while progressively scaling its footprint through strategic acquisitions, technological advancements, and management restructuring to sustain growth in the competitive healthcare sector.